Intellia Therapeutics Reports Q1 Results, Extends Cash Runway to 2028 with $207M Offering Proceeds
NTLA has more than doubled off its 52-week low of $6.83.
Summary
Intellia Therapeutics reported Q1 2026 financial results, highlighting a reduced net loss and an extended cash runway into 2028, bolstered by a recent $207 million public offering.
Key Events · Earnings and Guidance · NTLA
-
Q1 2026 Financial Results
Reported a net loss of $96.2 million for Q1 2026, an improvement from $114.3 million in Q1 2025, driven by reduced R&D expenses.
-
Extended Cash Runway
Proceeds from the April 2026 public offering, totaling approximately $207 million, are expected to fund operations at least into 2028, extending the previous guidance of the second half of 2027.
-
Lonvo-z Regulatory Progress
Initiated a rolling Biologics License Application (BLA) submission to the FDA for lonvo-z in Hereditary Angioedema (HAE), targeting a U.S. launch in the first half of 2027.
-
Nex-z Clinical Trial Resumption
Patient screening has resumed for the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z for ATTR amyloidosis, following the FDA lifting clinical holds.
Analysis · NTLA · Life Sciences
Intellia Therapeutics' first-quarter results show a reduced net loss and R&D expenses. Critically, the company confirmed that proceeds from its recent $207 million public offering have extended its cash runway into at least 2028, providing significant financial stability for its ongoing clinical programs, including the rolling BLA submission for lonvo-z and resumed Phase 3 trials for nex-z. This extended runway is a key positive for a clinical-stage biotech.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1838 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NTLA was trading at $14.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $6.83 to $28.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.